Altium Limited
.png)
ALU Details
-
Focusing on margins: Altium Limited (ASX: ALU) stock rose over 4% on July 20, 2016 at the back of good performance of the information technology sector. The rise led to total returns of 54.75% in the last six months alone for the company. Still the stock is trading at a reasonable valuation with a very cheap P/E. The group generated a sales growth by 22% in the first half of 2016 while the revenue rose 13%. ALU expects $100 million in revenue for 2017. Altium is also focusing on margins and improved its EBITDA margin for existing business to 27.5% against 26.7% (excluding revenue and costs from acquisitions). The group witnessed 23% rise in number of new AD licenses sold.
-
Recommendation: We give a “Hold” recommendation at the current price of $7.11
.png)
Altium Limited’s revenue sources (Source: Company Reports)
Sirtex Medical Limited
.png)
SRX Details
-
Solid dose sales despite turmoil: Sirtex Medical Limited (ASX: SRX) continued to rise over 4.3% on July 20, 2016 leading to over 12.2% jump in the last four weeks, at the back of overall strong performance by the Healthcare sector. Investors were happy with the group’s dose sales of SIR-Spheres® Y-90 resin microspheres performance for fiscal year of 2016, which delivered a 16.4% rise on a year over year basis across the globe. Sirtex generated a rise in the upper end of its guidance of 15-17% dose sales. Americas delivered solid second half and full year dose sales growth of 19.2% and 19.0%, respectively. But, EMEA and APAC performance is what boosted the investor’s sentiment as the regions recorded full year dose sales growth of 11.2% and 8.9% respectively, withstanding Brexit impact.
-
Recommendation: We maintain our “Buy” recommendation on the stock at the current price of $31.45
Magellan Financial Group Ltd
.png)
MFG Details
-
Launched Magellan Infrastructure fund: Magellan Financial Group Ltd (ASX: MFG) stock rose over 3% on July 20, 2016 as the group launched Magellan Infrastructure fund. This fund offers investors with a specialized and focused global infrastructure fund while substantially hedging the foreign currency exposure of the fund. Magellan’s third Exchange-Quoted Managed Fund (EQMF) is among the rapidly growing segments of the funds management industry.
-
Recommendation: We maintain our “Buy” recommendation on the stock at the current price of $22.31
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.